Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30048804HIVENSG00000007047.16protein_codingMARK4NoNo57787Q96L34
TVIS20001637HPVENSG00000007047.16protein_codingMARK4NoNo57787Q96L34
TVIS20053906HPVENSG00000007047.16protein_codingMARK4NoNo57787Q96L34
TVIS20023937HPVENSG00000007047.16protein_codingMARK4NoNo57787Q96L34
TVIS20035553HPVENSG00000007047.16protein_codingMARK4NoNo57787Q96L34
TVIS20053920HPVENSG00000007047.16protein_codingMARK4NoNo57787Q96L34
TVIS20025807HPVENSG00000007047.16protein_codingMARK4NoNo57787Q96L34
TVIS44007615HTLV-1ENSG00000007047.16protein_codingMARK4NoNo57787Q96L34
TVIS44011709HTLV-1ENSG00000007047.16protein_codingMARK4NoNo57787Q96L34
TVIS44012287HTLV-1ENSG00000007047.16protein_codingMARK4NoNo57787Q96L34
TCGA Plot Options
Drug Information
GeneMARK4
DrugBank IDDB12010
Drug NameFostamatinib
Target IDBE0009482
UniProt IDQ96L34
Regulation Typeinhibitor
PubMed IDs26516587
CitationsRolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4.
GroupsApproved; Investigational
Direct ClassificationMethoxyanilines
SMILESCOC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
Pathways
PharmGKB
ChEMBLCHEMBL2103830